| Janssen Alzheimer Immunotherapy Patent applications |
| Patent application number | Title | Published |
|---|
| 20120070379 | IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 03-22-2012 |
| 20110306756 | Prevention and Treatment of Amyloidogenic Disease - The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide, active fragments thereof or an antibody thereto. | 12-15-2011 |
| 20110287042 | A-Beta Immunogenic Peptide Carrier Conjugates and Methods of Producing Same - The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods. | 11-24-2011 |
| 20110229413 | TREATMENT OF AMYLOIDOGENIC DISEASES - The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment. | 09-22-2011 |
| 20110160437 | METHODS OF PURIFYING ANTI A BETA ANTIBODIES - The present application provides methods of purifying Aβ binding proteins having a Fc region, for example, anti-Aβ antibodies or antibody fusions, by adsorbing the Aβ binding protein to a Fc binding agent, such as, for example, Protein A or Protein G, followed by a wash with a divalent cation salt buffer to remove impurities and subsequent recovery of the adsorbed Aβ binding protein. The present application also features methods of eluting the purified Aβ binding protein as well as the incorporation of the methods within a purification train. Kits comprising components for carrying out the methods and instructions for use are also provided. | 06-30-2011 |
| 20110142823 | Humanized antibodies that recognize beta amyloid peptide - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. | 06-16-2011 |
| 20110135660 | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease. | 06-09-2011 |
| 20100315497 | MONITORING SYSTEM AND METHOD - A monitoring system includes an image capturing module, a displaying module, a face recognition module, a memory module, and a searching module. The image capturing module is configured for capturing images and videos. The face recognition module is configured for recognizing a number of human faces in the captured videos, and generating a number of groups of profile information each associated with a recognized face when the image capturing module captures the video. The memory module is configured for storing the captured videos and the profile information. The searching module is configured for receiving a group of input profile information, and searching whether a group of profile information stored in the memory module matches the group of the input information. The displaying module is configured for displaying the group of captured images associated with the group of profile information matched the group of input profile information. | 12-16-2010 |
| 20100266505 | IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 10-21-2010 |
| 20100221187 | TREATMENT OF AMYLOIDOGENIC DISEASES - The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment. | 09-02-2010 |
| 20100166752 | Anti A Beta Antibody Formulation - The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration. | 07-01-2010 |
